This website uses cookies to improve your user experience.
By using the site, you agree to our use of cookies.
Click here for more information about how we use cookies.
Application deadline: 25 Sep 2024
Institute: University College Dublin
Country: Ireland
More information: https://www.ucd.ie/freemanlab/openpositions/
Applications are invited from suitably qualified candidates for the position of a full-time 2 year fixed-term position as a Postdoctoral Researcher with Dr. Fiona Freeman’s team in Biomedical Engineering at UCD (https://www.ucd.ie/freemanlab/).
Osteosarcoma is an aggressive bone cancer that affects children and adolescents, with a 5-year survival rate of less than 20% for resistant forms. The interaction between cancer and the immune system has long been recognized as a critical aspect of chemoresistance. The successful candidate will carry out research on developing and in vitro testing of a conjugated STING-agonist nanoparticle as a potential add-on to chemotherapy for the treatment of chemoresistance. The project requires in-depth knowledge related to immunology and nanoparticle design, as well as in vitro assessments of nanoparticle-mediated therapies. This project is funded by the Science Foundation Ireland (SFI) Frontiers for the Future project, and the position is available from September 2024 with flexibility on the start date.
The successful candidate will have the opportunity to join a dynamic and motivated team investigating the use of innovative engineering techniques to better understand and develop novel therapeutics for treating osteosarcoma, a paediatric bone cancer. The lab's research interests include biomaterial design, 3D printing, developing in vitro and in vivo disease models, nanoparticle design, organ-on-a-chip, and immunoengineering. This position is related to the aim of developing a new nanoparticle-mediated immunotherapy to attack the tumour. It outlines an entirely new concept to treat this debilitating disease. The candidate will be responsible for nanoparticle development, characterization, and 2D and 3D in vitro testing of the therapeutic.